Posted by Michael Wonder on 19 Aug 2021
NICE recommends first treatment for rare blood disorder
19 August 2021 - People with a rare blood disorder have access to a new treatment following draft guidance from NICE.
In draft guidance published today, NICE has recommended midostaurin (Rydapt, Novartis) as a treatment for advanced systemic mastocytosis in adults.
